If you've searched "retatrutide price Australia" in the last few months, you've probably noticed something frustrating: there isn't one. No pharmacy shelf price, no PBS code, no manufacturer list price — because retatrutide is still an investigational medicine and has not been approved by the TGA. But "no price yet" isn't the same as "no idea". Australia already has a functioning private market for GLP-1 weight-loss medicines, and that market tells us a lot about what a retatrutide price in Australia is likely to look like when the drug eventually arrives.

This piece is deliberately different from the usual efficacy write-up. Instead of the 28.3% headline from TRIUMPH-1, we're doing the boring, useful thing: modelling the money.

Why there is no retatrutide price in Australia yet

Retatrutide is Eli Lilly's investigational triple-agonist — it acts on three receptors (GLP-1, GIP and glucagon), where semaglutide (Ozempic, Wegovy) acts on one and tirzepatide (Mounjaro, Zepbound) acts on two. You can read the mechanism breakdown in what is retatrutide.

The pricing sequence is fixed and it runs in this order:

  1. Phase 3 data. TRIUMPH-1 reported in May 2026, TRIUMPH-4 (knee osteoarthritis) followed, and in July 2026 Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3 — the latter in adults with severe obesity and established cardiovascular disease, with average weight loss up to 22.6% at 80 weeks.
  2. Regulatory filing. Lilly has said it plans to submit to the US FDA in Q1 2027, with an Australian TGA submission expected from 2027 onward.
  3. TGA registration. Only after registration does a sponsor set an Australian list price.
  4. PBS consideration. A separate, slower process — and the one that actually decides what you pay.

Until step 3, any "retatrutide cost Australia" figure you see is an estimate, not a price. More on the regulatory gates in clinical trials.

What Australians pay for weight-loss injections right now

This is the honest benchmark, because retatrutide will be priced into an existing market, not a vacuum.

Reported 2026 private-script pricing in Australia sits roughly here:

  • Mounjaro (tirzepatide): commonly quoted around $350–$500 a month at maintenance doses, with some higher-dose patients reporting more, and lower starting doses cheaper. Telehealth and clinic comparisons in 2026 have shown a spread of $90+ a month between providers for the identical medicine.
  • Wegovy (semaglutide): commonly quoted in the $269–$460 a month range depending on dose.
  • Ozempic on a PBS script (type 2 diabetes only): a fraction of that, because it's subsidised — which is exactly the point.

Neither Mounjaro nor Wegovy is currently PBS-subsidised for weight management, so most Australians using them for obesity are paying full private cost. That's the baseline retatrutide has to compete against.

Modelling the retatrutide cost in Australia: three scenarios

Nobody can quote you a number. But you can reason about the range.

Scenario 1: premium launch pricing

New-in-class medicines typically launch at or above the top of the existing market. Retatrutide is a first-in-class triple agonist with the strongest phase 3 weight-loss data seen so far, so a launch price at the upper end of — or slightly above — current tirzepatide pricing would surprise nobody. In today's dollars that implies something in the ballpark of $450–$700+ a month privately, likely tiered by dose.

Scenario 2: a genuinely competitive 2028 market

By the time retatrutide could plausibly reach Australian pharmacies, the landscape will be crowded: tirzepatide, semaglutide (with generic semaglutide already emerging in some markets), and oral options including Lilly's own orforglipron. More competitors generally means more discounting, bundled clinic pricing, and three-month dispensing deals. Competition is the single most likely force to pull an Australian retatrutide price down.

Scenario 3: PBS subsidy

This is the scenario that changes everything, and it's also the least certain.

Will retatrutide be on the PBS?

Look at the Wegovy precedent. In January 2026 the Pharmaceutical Benefits Advisory Committee recommended Wegovy for PBS subsidy — but not for obesity broadly. The recommendation targeted adults with established cardiovascular disease and obesity, mirroring the population studied in the SELECT trial, with price negotiations between the government and the sponsor following the recommendation.

Two things follow for retatrutide:

  • The cardiometabolic data matters more than the weight number. TRIUMPH-3 deliberately enrolled adults with severe obesity and established cardiovascular disease. That is precisely the kind of evidence a PBAC submission is built on.
  • Any first PBS listing would likely be narrow. Expect strict criteria (BMI thresholds plus comorbidity requirements) rather than open access for general weight management.

If retatrutide were ever PBS-listed, an eligible patient would pay the standard co-payment — a fraction of private cost — instead of several hundred dollars a month. Realistically, though, subsidy would come well after registration, not with it. The Australian access picture is tracked in australia.

What actually drives your out-of-pocket cost

Even in the private market, the sticker price isn't the whole cost. Budget for:

  • Dose escalation. Costs typically step up with dose, so month one is rarely month twelve.
  • Consultations and reviews. GP or clinic fees, plus pathology if indicated.
  • Pharmacy variation. Same script, different price — comparing dispensing pharmacies is the cheapest saving available.
  • Duration. Obesity medicines are treated as long-term therapy. Several of Lilly's ongoing phase 3 readouts in 2026 examine maintenance dosing strategies, which could eventually mean lower-cost, lower-dose maintenance phases — a meaningful factor in lifetime cost.
  • Tolerability. Gastrointestinal side effects are the most common reason people stop or step down, which changes real-world cost; see safety.

The Australian context

Around two in three Australian adults live with overweight or obesity, and roughly 66.8% is the figure most commonly cited. At $400–$600 a month, effective pharmacotherapy is priced out of reach for a very large share of that population. That's why the PBS question — not the trial data — is the one that determines whether retatrutide becomes a public health tool or a private purchase.

Want the price and TGA news the day it's confirmed rather than three weeks later? Join the free updates list — we'll email you when Australian pricing, submission and approval milestones are officially announced.

FAQ

How much will retatrutide cost in Australia?

There is no Australian price yet, because retatrutide isn't TGA-approved. Based on what tirzepatide and semaglutide currently cost on private scripts here (roughly $270–$500+ a month), a private retatrutide price at or above the top of that range is a reasonable expectation — but it remains an estimate, not a quote.

Will retatrutide be covered by the PBS?

Not at launch, if it follows the pattern of other obesity medicines. Wegovy was only recommended for PBS subsidy by the PBAC in January 2026, and then for a narrow group with established cardiovascular disease and obesity — so any retatrutide listing would likely be similarly restricted and would come years after registration.

When will retatrutide be available in Australia?

Eli Lilly has indicated it plans to file with the US FDA in Q1 2027, with Australian regulatory submission expected from 2027. Allowing for TGA evaluation time, Australian availability realistically sits beyond that — and no date has been confirmed.

Is retatrutide cheaper than Mounjaro?

Unknown, and unlikely at launch. Newer in-class medicines typically enter at or above existing pricing; downward pressure usually arrives later, as more competitors (including oral options and generic semaglutide) enter the market.

Sources

Disclaimer: retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company. Retatrutide is an investigational medicine and is not approved by the TGA for any use in Australia. All prices mentioned are publicly reported market figures for other medicines and are indicative only — they are not offers, quotes or forecasts. This article is general information, not medical advice. Always speak with your GP or a qualified health professional about weight management, medicines and your individual circumstances.